1. Scrip
  2. >>Business
  3. >>Deals

Pfizer's Dolsten On Finding Ways To “Accelerate External Science”

Part 2 Of 2

 
• By Jessica Merrill

Worldwide President of R&D Mikael Dolsten talked to Scrip about Pfizer's busy business development track record and the company's ambition to maintain its leadership in breast cancer.

big fish eating small fish
Pfizer has been an active dealmaker this year • Source: Shutterstock

Pfizer Inc. has been on an M&A buying spree over the last year, powered by the unprecedented returns from its COVID-19 vaccine Comirnaty and antiviral Paxlovid and with the aim of finding the next big commercial wins to fuel growth in the second half of the decade. For worldwide president of R&D Mikael Dolsten, that means finding new assets and talent and finding ways to continue successfully building the R&D organization as new groups join the big pharma.

Dolsten sat down with Scrip for an interview at the Galien Foundation Forum in New York on 26 October, and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Second Quarter M&A Activity Looks Like More Of The Same, Mostly

 
• By Joseph Haas

The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By Kevin Grogan

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By Joseph Haas

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By Kevin Grogan

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

More from Business

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By Kevin Grogan

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By Joseph Haas

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By Kevin Grogan

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.